Skip to content

Harmony Biosciences Holdings, Inc. HRMY Accretion (Amortization) of Discounts and Premiums, Investments

Accretion (Amortization) of Discounts and Premiums, Investments at other companies

Acadia Pharmaceuticals logo
Acadia PharmaceuticalsACAD
$453K-78.6%
Praxis Precision Medicines, Inc. logo
Praxis Precision Medicines, Inc.PRAX
$655K-46.7%
Ultragenyx Pharmaceutical logo
Ultragenyx PharmaceuticalRARE
$1M-50.0%
iRhythm Holdings, Inc.
 logo
iRhythm Holdings, Inc. IRTC
$730K+17.9%
Rapport Therapeutics, Inc. logo
Rapport Therapeutics, Inc.RAPP
$364K-16.5%
Neurocrine Biosciences logo
Neurocrine BiosciencesNBIX

Other financials

Income statement

See full
Revenue$215.4M+16.6%
Gross profit$170.9M+11.9%
Operating income$37.3M-33.7%
Net income$32.5M-28.7%
EPS (diluted)$0.55-29.5%

Balance sheet

See full
Cash & equivalents$589.4M+20.5%
Total debt$164.6M-7.2%
Total equity$910.3M+26.3%
Total assets$1.3B+20.5%

Cash flow

See full
Operating cash flow$27.8M-18.3%
CapEx$107.0K-79.1%
Free cash flow$126.0M+67.9%

Valuation

See full
Market cap$1.99B-14.9%

Profitability

See full
Gross margin76.5%-1.8pp
Operating margin21.1%-5.1pp
Net margin16.2%-4.3pp
FCF margin40.1%+9.5pp

Returns & leverage

See full
Return on equity17.9%-6.9pp
Debt / equity0.2×-0.1×
Current ratio3.6×-0.1×

Where this comes from

Reported directly by Harmony Biosciences Holdings, Inc. in its filing.

Tagged under the XBRL concept us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments.

The official record: Harmony Biosciences Holdings, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Harmony Biosciences Holdings, Inc.'s accretion (amortization) of discounts and premiums, investments.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Harmony Biosciences Holdings, Inc.'s accretion (amortization) of discounts and premiums, investments?
Harmony Biosciences Holdings, Inc. (HRMY) reported accretion (amortization) of discounts and premiums, investments of $220K in Q1 2026.
How has Harmony Biosciences Holdings, Inc.'s accretion (amortization) of discounts and premiums, investments changed year-over-year?
Harmony Biosciences Holdings, Inc.'s accretion (amortization) of discounts and premiums, investments decreased by 51.2% year-over-year, from $451K to $220K.
What is the long-term trend for Harmony Biosciences Holdings, Inc.'s accretion (amortization) of discounts and premiums, investments?
Over 3 years (2022 to 2025), Harmony Biosciences Holdings, Inc.'s accretion (amortization) of discounts and premiums, investments has grown at a 52.1% compound annual growth rate (CAGR), from $432K to $1.52M.
What does accretion (amortization) of discounts and premiums, investments mean?
This represents the non-cash adjustment to the carrying value of investment securities to reflect the amortization of premiums or the accretion of discounts over the life of the investment. It ensures that the interest income recognized on the income statement aligns with the effective interest method. This metric helps investors understand the non-cash components of investment returns.